ICG for Head and Neck Tumors During Surgery
This study is for adults with head and neck cancer (squamous cell carcinoma) who are at risk of their cancer returning. Researchers are looking at whether a special dye called Indocyanine Green (ICG) can help surgeons see tumor tissue better during an operation. You would receive ICG as an injection before surgery, and then imaging would be done during the surgery. The main goal is to see how well ICG helps identify cancer cells. The study is currently recruiting about 30 participants and will last approximately 6 weeks for each person.
- Study design
- This is an interventional study planning to enroll 30 participants. The phase of the study is not specified.
- What's involved
- You would have standard medical visits, receive an Indocyanine Green (ICG) injection, and have imaging done during surgery. Your participation in the study would last about 6 weeks.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint is measured from the time of surgery until final pathology results are available, which is about 2 weeks.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Intraoperative Molecular Imaging Using ICG for Head and Neck Tumors
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Jason Newman, MD, FACS · PRINCIPAL_INVESTIGATOR · Medical University of South Carolina
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Estimates of sensitivity and specificity using ICG.From time of surgery until final pathology results are available (about 2 weeks)
Sensitivity (specificity) will be estimated as the proportion of pathologically positive (negative) samples that do (do not) fluoresce using ICG.